Altimmune, Inc.
ALT
Rank in Stocks
#13136
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on... Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Share Price
$2.12
Last synced: 2026-11-09
Market Cap
$412.38M
Change (1 day)
1.92%
Change (1 year)
-50.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Altimmune, Inc. (ALT)
Category
Healthcare
Operating Margin for Altimmune, Inc. (ALT)
Operating Margin as of November 2026 TTM: -323,306.45%
According to Altimmune, Inc.'s latest financial reports, its current operating margin (TTM) is -323,306.45%. At the end of 2025 the company had an operating margin of -230,460.98%.
Operating Margin history for Altimmune, Inc. from 2005 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -323,306.45% | 40.29% |
| 2025 | -230,460.98% | -55.32% |
| 2024 | -515,860.00% | 2,190.82% |
| 2023 | -22,518.54% | -117.45% |
| 2022 | 129,029.41% | -5,971.38% |
| 2021 | -2,197.60% | 228.24% |
| 2020 | -669.50% | 80.95% |
| 2019 | -370.00% | -10.76% |
| 2018 | -414.61% | -99.67% |
| 2017 | -125,401.20% | 58,125.94% |
| 2016 | -215.37% | 573.45% |
| 2015 | -31.98% | -68.02% |
| 2014 | -100.01% | 65.28% |
| 2013 | -60.51% | 143.11% |
| 2012 | -24.89% | -48.49% |
| 2011 | -48.32% | -56.93% |
| 2010 | -112.19% | 19.00% |
| 2009 | -94.28% | -11.96% |
| 2008 | -107.09% | -4.98% |
| 2007 | -112.70% | -273.04% |
| 2006 | 65.13% | 17.35% |
| 2005 | 55.50% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -100.00% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Altimmune, Inc.'s operating margin
What is Altimmune, Inc.'s operating margin?
Altimmune, Inc.'s operating margin is -323,306.45%, as of Nov 2026.
What was Altimmune, Inc.'s operating margin in 2025?
In 2025, Altimmune, Inc.'s operating margin was -230,460.98%, compared with -515,860.00% in 2024.
How has Altimmune, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Altimmune, Inc.'s operating margin was highest in 2022 (129,029.41%) and lowest in 2024 (-515,860.00%).
How does Altimmune, Inc.'s operating margin compare with similar companies?
Altimmune, Inc.'s operating margin (-323,306.45%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.